Pediatric Augmentin Dosing
For β-lactamase-producing organisms (such as β-lactamase-producing Haemophilus influenzae or Moraxella catarrhalis), use amoxicillin-clavulanate at 45 mg/kg/day (of the amoxicillin component) divided into 3 doses, or 90 mg/kg/day divided into 2 doses 1, 2, 1.
Standard Dosing Regimens
For β-Lactamase-Producing Pathogens
The IDSA/PIDS pediatric pneumonia guidelines specify two acceptable dosing options for oral amoxicillin-clavulanate when treating β-lactamase-producing organisms 1, 2, 1:
- 45 mg/kg/day in 3 divided doses (15 mg/kg per dose)
- 90 mg/kg/day in 2 divided doses (45 mg/kg per dose)
Both regimens refer to the amoxicillin component of the combination.
High-Dose Formulation (Augmentin ES-600)
For more severe infections or when enhanced coverage is needed, Augmentin ES-600 provides 90 mg/kg/day divided every 12 hours 3. This formulation contains 600 mg amoxicillin/42.9 mg clavulanate per 5 mL and is specifically designed for:
- Persistent or recurrent acute otitis media
- Risk factors for drug-resistant S. pneumoniae
- β-lactamase-producing organisms
The FDA label specifies this is for pediatric patients ≥3 months old, with dosing based on weight 3:
- 8 kg: 3.0 mL twice daily
- 12 kg: 4.5 mL twice daily
- 16 kg: 6.0 mL twice daily
- 20 kg: 7.5 mL twice daily
Clinical Context and Considerations
When to Use Standard vs. High-Dose
Use standard-dose (45 mg/kg/day in 3 doses) for:
- Mild to moderate infections
- Children ≥2 years old
- No recent antibiotic exposure (<4 weeks)
- Not attending daycare
Use high-dose (90 mg/kg/day in 2 doses) for 4:
- Moderate to severe illness
- Children <2 years old
- Recent antibiotic exposure (within 30 days)
- Daycare attendance
- High local prevalence of β-lactamase-producing H. influenzae
Important Caveats
Do not exceed adult doses - the guidelines explicitly state that pediatric oral therapy doses should not exceed standard adult dosing 1, 2, 1.
Clavulanate content varies - Different Augmentin formulations contain different amounts of clavulanate. The ES-600 formulation (42.9 mg/5 mL) is NOT interchangeable with standard suspensions (200 mg/5 mL contains 28.5 mg clavulanate; 400 mg/5 mL contains 57 mg clavulanate) 3.
Gastrointestinal side effects - Diarrhea is the most common adverse effect, occurring in approximately 17-26% of children 5. The high-dose formulation may cause more GI disturbances, though recent evidence suggests lower clavulanate concentrations (2.85-3.2 mg/kg/day) may reduce diarrhea rates without compromising efficacy 5.
Administration
Give at the start of meals to minimize GI intolerance and enhance clavulanate absorption 3. The reconstituted suspension is stable for 10 days under refrigeration. Shake well before each use.
Duration of Therapy
Treat for 10 days for most respiratory infections 1, 2, 1. This is the best-studied duration, though shorter courses may be effective for milder disease managed outpatient.
Special Populations
Critically ill children may require more frequent dosing (every 4 hours instead of every 6 hours) due to augmented renal clearance, particularly post-cardiac surgery or in sepsis 6, 7. Standard dosing often results in subtherapeutic levels in this population.